PHRENILIN FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PHRENILIN FORTE (PHRENILIN FORTE).
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
| Metabolism | Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2. |
| Excretion | Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally. |
| Half-life | Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease. |
| Protein binding | Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin. |
| Volume of Distribution | Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg. |
| Bioavailability | Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete). |
| Onset of Action | Oral: 15-30 minutes for analgesic effect. Peak effects at 1-2 hours. |
| Duration of Action | Analgesic duration: 4-6 hours. Butalbital's sedative effects may persist longer due to long half-life. |
| Molecular Weight | Butalbital: 224.26 Da; Acetaminophen: 151.16 Da |
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
| Dosage form | CAPSULE |
| Renal impairment | Not formally established. Acetaminophen component: avoid in severe renal impairment (CrCl <10 mL/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for CrCl 10-50 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity. |
| Pediatric use | Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred. |
| Geriatric use | Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly. |
| 1st trimester | Insufficient human data; animal studies suggest risk. Fetal abnormalities reported with butalbital (barbiturate) and acetaminophen at high doses. Use only if clearly needed. |
| 2nd trimester | Risk of fetal harm from butalbital (withdrawal, bleeding) and acetaminophen (hepatotoxicity in overdose). Avoid unless benefit outweighs risk. |
| 3rd trimester | Barbiturates cause neonatal withdrawal, respiratory depression, and bleeding due to vitamin K deficiency. Acetaminophen safe at therapeutic doses but avoid high doses. |
Clinical note
Comprehensive clinical and safety monograph for PHRENILIN FORTE (PHRENILIN FORTE).
| Placental transfer | Both butalbital and acetaminophen cross the placenta. Butalbital reaches fetal serum levels 50-100% of maternal levels; acetaminophen crosses readily. |
| Breastfeeding | Butalbital is excreted into breast milk in low levels; monitor infant for sedation, poor feeding, and weight gain. Acetaminophen is considered compatible. Use with caution, especially with prolonged therapy. |
■ FDA Black Box Warning
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
| Serious Effects |
Hypersensitivity to butalbital, acetaminophen, or caffeinePorphyriaSevere hepatic impairmentSevere respiratory depressionAcute or chronic alcoholismConcomitant use of MAOIs (risk of hypertensive crisis from caffeine)
| Precautions | Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment. |
| Food/Dietary | Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital. |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe (limited data; consider risk vs benefit) |
| Teratogenic Risk | First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, hepatic function, and signs of barbiturate dependence. Fetal monitoring: assess growth, non-stress test, and biophysical profile if used chronically. Monitor neonate for withdrawal symptoms if used near term. |
| Fertility Effects | No known effects on fertility from acetaminophen or caffeine. Butalbital may induce hepatic enzymes affecting sex hormone metabolism, potentially altering menstrual cyclicity or ovulation; clinical significance unclear. |
| Clinical Pearls | Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment. |
| Patient Advice | Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen. · Avoid alcohol while taking this medication to prevent liver toxicity. · This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you. · Do not use with other products containing acetaminophen to avoid overdose. · If you have a history of substance abuse, inform your doctor; this drug can be habit-forming. · Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors). · Store at room temperature away from moisture and heat. |